Advanced Parkinson's disease
Advanced Parkinson's disease
PD is an incurable neurodegenerative disorder that results from a deficiency of dopamine in the brain. The advanced stage of PD is not precisely defined; however, symptoms of advanced disease include problems with memory and balance, stiff facial muscles, involuntary movements, and slow or slurred speech. Essentially, advanced-stage Parkinson’s is associated with the sufferer’s symptoms becoming progressively worse and their condition deteriorating markedly.
The medical management of advanced Parkinson’s is often complex and fraught with difficulties; patients in the later stages often have a poorer response to medication, meaning that higher individual doses/more frequent dosing is often required. The treatments either do not work as well, or they may only be efficacious for a limited period, making the addition of other medications often necessary.
With advancing disease, as the number of medications is increased in an attempt to maintain symptom control, side effects become increasingly problematic. It becomes ever more challenging to achieve a medication regimen that keeps the patient mobile while at the same time does not create side effects that outweigh the benefits of treatment.
This website serves as a valuable resource for physicians treating patients with advanced PD, providing information, highlighting the latest research, collating the views of thought leaders, and listing forthcoming congresses in the field. This site serves to augment knowledge within the medical community of this complex stage of PD and thus help guide clinical decision making.
As information resource for the scientific community, we are always looking for ways to improve our site. If you have any suggestions for additional content, please contact mary.read@touchbriefings.com, jenny.charlton@touchbriefings.com . We welcome your input.
Editor's Choice
Motor fluctuations and dyskinesias in Parkinson’s disease (PD) patients cause severe disability and may not be adequately controlled by oral treatment. Longterm therapy options include deep brain...
A report providing evidence that patients with LRRK2 monogenetic Parkinsonism are well suited candidates for deep brain stimulation treatment. ...
Upcoming events
28th August - 1st September 2010
The scientific programme will consist of plenary lectures, a number of symposia, educational update sessions, brainstorming sessions and poster sessions. In addition, Breaking News symposia, focusing on the latest developments in preclinical and clinical research in neuropsychopharmacology, will be...
12th - 15th September 2010
The American Neurological Association (ANA) is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of...
26th - 29th September 2010
The meeting theme – Diversity, Collaboration and Dignity – will be explored in depth by the scientific program. Geriatric mental health covers a broad array of issues and IPA will consider some of these topics at this meeting:Suicide and suicide prevention in the elderlyBPSD in home living and...
28th September - 1st October 2010
The 2nd World Parkinson Congress | WPC 2010 aims to provide an international forum for the latest scientific discoveries, medical practices and caregiver initiatives related to Parkinson’s disease. By bringing physicians, scientists, allied health professionals, caregivers and people with...
New Drug Approved for Advanced Parkinson's Disease
| The Touch Neurology Advanced Parkinson’s disease website has been supported by an unrestricted grant from Solvay Pharmaceuticals |
![]() |





